1 COUNSELING VIVITROL PATIENTS FOR RECOVERY David R Gastfriend MD Director, FADAA Peer Mentoring Project Scientific Advisor, Treatment Research Institute Chief Architect, CONTINUUM The ASAM Criteria Decision Engine Disclosures: Shareholder and former employee of Alkermes, Inc. Royalty recipient from the American Society of Addiction Medicine for the licensing of CONTINUUM Chief Medical Officer, DynamiCare Health
2 COUNSELING VIVITROL PATIENTS FOR RECOVERY Why? What? Who? How?
3 WHY? Why is Drug Dependence So Tough? Why Has Counseling Dominated Care? Why Do Researchers Push Meds? Why Don t We Emphasize Adherence?
4 Public Health Model of an Epidemic Addiction: Promoters Responses Agent : receptor affinity, purity, faster routes of administration : blockade, catabolism Environment : access, lower cost, prescribing : culture change, neighborhood policing, sanctions Host : genetic, congenital & acquired vulnerability, comorbidity : resilience, coping
5 Brain Reward: With us throughout evolution
6 Brain Regions & Circuits in Addiction EXECUTIVE FUNCTION INHIBITORY CONTROL MOTIVATION/ DRIVE PFC OFC ACG D. Striatum NAcc Amyg Hipp VP REWARD MEMORY/ LEARNING
7 Pathophysiology NIDA Drugs, Brains, and Behavior The Science of Addiction Website. Available at: Accessed June 1,2011. Fowler JS et al. Sci Pract Perspect. 2007;3:4-16. Role: Cortex Decision making Thinking Reasoning Learning Interventions Psychosocial Therapies 12 Step Programs Monitoring Limbic Region Role: Basic Drives Experience of Reward, Euphoria Interventions Agonist Medications Antagonist Medications
9 Oral Medication Discontinuation Rates VA Study (Hermos et al., ACER 2004) Percent of Patients Months Treatment durations virtually identical for both drugs 35% filled for 1 mo or less; 50% for 2 mos; 75% refill 5 mos. Discontinuation risk: X greater than for statins or SSRIs
10 Oral Naltrexone Adherence in Alcohol Dependence Nonadherent 86% Adherent 14% Medstat MarketScan Insurance Claims Database ( ) Over 5 million employees from 50 large national employers 1138 oral NTX patients 52% did not refill even once (Median = 1 Rx) Only 14% filled prescriptions for 6 months Stephenson et al., American Academy of Addiction Psychiatry, 2006
11 Oral Naltrexone Adherence in Alcohol Dependence Non-adherent patients were significantly more likely to have Inpatient detoxification admissions Non-alcohol specific hospital admissions Non-alcohol specific ER visits No counseling participation Stephenson et al., American Academy of Addiction Psychiatry, 2006
12 Percent Retained Agonists: Treatment Retention 100 Mean retention on BUP: Yser, Addiction 2014: 66 days Baser, AJMC, 2011: 69 days Fishman, CPDD 2011: 67 days (adol/young adults) 92% relapse within 8 wks of taper (Weiss et al., 2011) 80 73% Hi Meth % Bup 53% LAAM % Lo Meth Study Week Johnson RE, et al (2000)
13 Development of XR-NTX Problem of nonadherence was well understood by The promise of naltrexone was undermined by nonadherence NIAAA and NIDA awarded grants that led to development of Medisorb * technology XR-NTX uses the Medisorb extended-release properties, first introduced in Risperdal Consta * Medisorb is a registered trademark of Alkermes, Inc. Risperdal Consta are registered trademarks of Janssen Pharmaceutical. Reference: 1. NIDA Monograph, Narcotic Antagonists: The Search for Long-acting Preparations
14 % of Members With A Refill Persistence of Monthly Refills Private national pharmacy claims data in all Alcohol Use Disorder patients who filled an initial Rx 60% Medication Adherence Rate Comparison 50% XR-NTX Acamprosate Disulfram Naltrexone N=133 N=3012 N=1006 N= % 30% 20% 10% 0% 2 months 3 months 4 months 5 months 6 months 9 months # of Months After Initial Rx Was Filled Un H, Addiction Health Services Research Conference, Boston 2008
15 WHAT? What is Adherence Pharmacotherapy? What is the Clinical Benefit? Why Go Through Detox? What are the Side Effects? What are the Long-Term Effects? What Happens to Quality of Life? What Happens to Treatment & AA? What Happens to Enjoyment & Pleasure?
16 INJECTABLE XR-NTX FOR OPIOID DEPENDENCE: A Double-Blind, Placebo-Controlled, Multicentre Randomised Trial (The Lancet,2011;377: ) E Krupitsky 1, EV Nunes 2, W Ling 3, A Illeperuma 4, DR Gastfriend 4, BL Silverman 4 1 Bekhterev Research Psychoneurological Institute, St Petersburg State Pavlov Medical University, St Petersburg, Russia 2 New York State Psychiatric Institute and Department of Psychiatry, Columbia University, New York, NY, USA 3 Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles, CA, USA 4 Alkermes, Inc., Waltham, MA Funding: Alkermes Inc. Objective: To assess the efficacy, safety and patient-reported outcomes of an injectable, once monthly extended-release formulation of the opioid antagonist naltrexone for the treatment of patients with opioid dependence after detoxification 9
17 Secondary Endpoint: Treatment Retention VIVITROL (n=126) Placebo - Median days of treatment=96 VIVITROL - Median days of treatment=168 Krupitsky E et al. Lancet. 2011:
18 6-Month Retention on XR-NTX: 3 Studies Health Prof ls Study (N=48) 1-Year Safety Study (N=101) Phase III (N=126)
19 WHAT? What is Adherence Pharmacotherapy? Prescribing to sustain a long-term clinical benefit What is the Clinical Benefit? Prevention of relapse Creating a biochemical foundation for recovery Why Go Through Detox? The Pay Now, Fly Later Plan What are the Long-Term Effects? Retention in counseling Decreased craving, drug use, relapse to dependence Stability for building coping skills & relationships NOT, in & of itself, recovery or health
20 Ask your doctor if taking a pill to solve all your problems is right for you.
21 XR-NTX: Induction How Do We Start? There is no single proven method, however, success has been found with Inpatient AND Outpatient approaches Success = >50% of patients retained through 1 st XR-NTX injection without precipitated withdrawal KEY: Close contact & attention to the patient s changing needs Setting expectations, providing support AND structure
22 XR-NTX: WD Symptoms Upon Initiation Withdrawal is commonly compared to the flu Aches, pains, insomnia, nausea, anergia Anxiety, irritability, dysphoria, anhedonia Aggressive symptomatic treatment helps Insomnia: zolpidem, trazodone, quetiapine GI distress: H2 blockers Anxiety/hyperarousal: clonazepam, clonidine Most symptoms remit in 2-4 weeks Prolonged symptoms are rare & likely represent additional psychopathology
23 Improvement in Function & Quality of Life Mean SF-36 physical component scores at Baseline were similar in the XR-NTX and placebo groups (50.4 vs. 50.7) and remained at or above U.S. norms (=50) at endpoint. Mean SF-36 mental component scores were similar at Baseline (35.0 vs. 35.4), but at endpoint, the XR-NTX group had normalized to 50.4 vs for placebo (~half an SD below normal).
24 XR-NTX & Self-Help Attendance (Alcohol) % Attending Self-Help Over 6 Months: All Patients (N=624) Mean % subjects Prior 30 days Placebo XR-NTX 190 mg XR-NTX 380 mg
25 Moderately-or-Greater Hedonic Response During Treatment W Greater Hedonic Response During Treatment With XR-NTX XR-NTX & Pleasure (Alcohol) % Reporting Daily Activities as Pleasurable (N=72) ambling (N=26) Gambling (N=26) hopping (N=70) Shopping (N=70) sweets (N=72) Eating sweets (N=72) n sports (N=57) Exercising or participating in sports (N=57) cy foods (N=56) Eating spicy foods (N=56) r games (N=41) Playing cards or games (N=41) Reading (N=71) g sports (N=51) Reading (N=71) elations (N=55) Watching sports (N=51) friends (N=70) Sexual relations (N=55) od food (N=74) Being with friends (N=70) o music (N=71) Eating good food (N=74) alcohol (N=53) Listening to music (N=71) Drinking alcohol (N=53) O Brien et al., Am J Addiction % 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Very much Quite a bit Moderately 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 1
26 WHO? Who Should Be Considered for Meds? Who Benefits the Most from Vivitrol? Who Should NOT Receive Vivitrol? Is Vivitrol for Criminal Justice Patients? Who Should Be Involved in Care?
28 XR-NTX: For Whom? Motivated to be abstinent, opioid-free & undergo withdrawal Preparing to leave rehab or jail/prison opioid-free Monitored by judges, professional boards, employers, schools or sports teams that may not allow agonist treatment Structure & social supports in place (however, chronicity & severity can be either mild or severe) Rejects agonist treatment or has failed agonist treatment Succeeded with agonist treatment and wants to conclude it Wants shorter-term medication that can be easily concluded Late adolescent/emerging adult with shorter duration addiction Has both opioid and alcohol dependence
29 Conclusions: Who Responds? Traditional consensus on NTX-PO in opioid dependence: Mainly for narrow range of good prognosis patients, e.g., professionals, high motivation & good social supports. Monthly formulation: designed for adherencewillette 1976 No significant baseline predictors XR-NTX (vs. PBO) Good efficacy in higher severity patients, i.e., those with worse global severity with the CGI-S, higher craving, lower function (EQ-5D) & quality of life, & HIV+ Results suggest that XR-NTX was effective in promoting abstinence from opioids & preventing relapse after detox across a range of demographic and severity characteristics.
31 Selection Criteria: Offer XR-NTX If Patient Just withdrawn from opioids; or abstinent but intense craving Leaving inpatient rehab or incarceration Has begun intermittent use, but not yet dependent relapse Despite maintenance agents, frequently uses opioids anyway Discontinuing maintenance as a landing pad transition Young adult or late adolescent Subject to drug testing or job sanctions for maintenance Dependent on both opioids and alcohol Treatment Matching is key: There is no superior approach except the one that works for the particular patient! Segregated care = BAD care; patients need integrated care
32 HOW? How Do You Describe Vivitrol At Intake? How Do You Address Ambivalences? How Should Family Be Included? Doctors & Other Strangers How Will I-We-They Know If It Works? How to Contract For Success Logistics for Successful Adherence Exploring The Patient s Perceptions How Does Craving Change?
33 XR-NTX in Rehab: Data Sources Administrative records from 3 inpatient CRC rehabs in PA CRC is the largest U.S. provider of specialized behavioral healthcare, treating >30,000 individuals daily Electronic records characterized 7,687 opioid dependent detox/rehab inpatients in terms of demography, diagnosis, payer & hospital course. Conclusions 1. XR-NTX patients were significantly less likely to leave AMA, more likely to complete rehab, have longer LOS & greater entry to continuing care. 2. Women: as likely as men to receive XR-NTX; Race did not appear to be a factor in treatment selection. 3. XR-NTX can be successfully administered to opioid dependent patients after detox & before discharge from inpatient rehab.
34 XR-NTX in Rehab: Results Injected Not injected Not Prescribed p<.001 vs XR- NTX (Days)
35 We find that all of us, as a society, are to blame, but only the defendant is guilty.
36 Note: data were annualized because offenders in the XR-NTX group were in DUI/Drug Court for a longer mean time than offenders in the Control group (13 vs. 11 months)
37 CRIMINAL JUSTICE Study 4: XR-NTX in Missouri Probation & Parole Naturalistic outpatient treatment, retrospectively analyzed; XR-NTX (N=156), Oral Naltrexone (N=45), Bup/Nal (N=168), No Meds (N=2513) Note: data were annualized because offenders in the XR-NTX group were in DUI/Drug Court for a longer mean time than offenders in the Control group (13 vs. 11 months)
38 HOW? Losing the: Craving (good!); High/Euphoria (OK); Escape (Uggh ) How Does Vivitrol Promote The 1st Step?: Awareness How Will I Cope?! Emotion Without Escape How to Talk About Vivitrol In A.A. Is There Spirituality After Technology? Foster Self-Efficacy: Via exploration, NOT discontinuation Remembering Vulnerability: Notes, Journals, Rating Scales Setbacks & Contingencies: Plan ahead, Restart How Long Should Vivitrol Be Continued? 6 mos? 12 mos? 13 mos? Or, based on criteria
39 Attitudes: Harmful & Helpful Attitudes that do a disservice to patients: If you re using drugs, you re not really sober; I did it the hard way If you just work the program, you won t need any drugs You can t treat a drug problem with a drug If you are on drugs, you can t speak at a meeting Attitudes that are justified by the science: We don t withhold medication from heart disease patients, saying: You have to stop smoking & lose weight on your own, like I did! Chronic diseases, like hypertension & asthma have meds. If we want addiction to be treated as equal to other medical illnesses, we need to accept the role of medicine in addiction treatment, too. Opioid patient on XR-NTX: I never understood it before but now I know how it is that non-addicts can just ignore drugs. And suddenly I see what it means that I really do have an addiction.
40 CRC Vivitrol Procedure Upon Admission Patients sign Alkermes Release form to verify if patient s insurance will cover medication History and Physical (within 24 hours of admission) Medical staff discusses Vivitrol as an option along with continuing care Mid-stay Lecture by medical staff regarding Vivitrol in conjunction with continuing care Information posted within center to promote Vivitrol Meet with designated staff members to verify benefit and continue the authorization process Before Discharge Medication shipped directly to center to facilitate injection prior to discharge Continuing Care with provider in home area is set for follow up injections CRC Provided Slide
41 XR-NTX: Testing the Blockade As many as half of patients will test blockade Usually during the 1 st month after detox; many on D/C day Thus, 1 st injection is better 2d before D/C; if given on last day & risk of testing, supplement with NTX-PO Most, after unsuccessfully testing 1-3 times, stop testing Rarely, (but reported) patient could use high amounts such that physical dependence could recur
42 XR-NTX: Managing Discontinuation Patients discontinue prematurely for innumerable reasons: it s the disease Better to regularly anticipate ambivalence & explore it in counseling If patient discontinues, remember that blockade can continue for as long as 6 weeks after injection It is not uncommon for a patient to want to restart XR-NTX later; This is a good sign that predicts a longer retention If patient restarts XR-NTX after cessation, must review need for detox
44 SoberRecovery : Sunday s Child I have a 19 year old son who did the usual progression from marijuana to percs and oxys. He went through several rehabs and relapses and was one week shy of completing an extended care program and hitting his one week clean mark. He relapsed and spent 5 weeks in a downward spiral that finally reached IV heroin. He reached out for help to his sponsor and others he knew from his program and AA. He went to his psychiatrist who suggested he try Vivitrol.
45 SoberRecovery : Sunday s Child The doctor first put him on a two week trial of oral naltrexone to see how he would tolerate the drug before committing to the shot. He waited 7 days after his last use before starting, but all the opiates were not out of his system. He went through a bad period of withdrawal, including a psychotic episode.
46 SoberRecovery : Sunday s Child He made it through the two weeks though and got his first shot mid- June. He's since had 3 shots, and is a little over 3 months clean. The stated side effects include depression, and I have noticed that he is a little more "edgy" right about when he gets the shot. When he was considering it, the guys from AA discouraged him, saying it was a crutch. He went ahead anyway, feeling that it was his last shot. The risk is that some addicts try to beat it with large quantities of dopethis produces overdose. The risk of overdose at "regular" dosages is also increased after it is stopped. So an addict needs to be really committed to recovery, because if you relapse, you are at greater risk of death. I was terrified when he told me he was trying it - but - it wasn't my choice, it was his. It seems to be working for him. He is working a program of recovery, holding a job, and attending college. He swears by the shots, and says he would recommend them to anyone.
47 Drug Users Forum: Bluelight.ru Yesterday 01:04 It cant really be done. Today is the 25th day after my vivitrol shot. (it lasts 30+ days) I also just got 1/2 g uncut #4 straight from the village of Azad Afghanistan. The plan was to wait until like the 35th day so i would get maximum benefit. But my dumb ass decided to try to break through the naltrexone blockade with about 80% pure heroin. I ended up using 3/10 g. i could feel something similar to a rush and could feel the heroin. But as I'm sitting here typing 5 minutes later there is not much euphoria at all. Okay now im starting a slight nod. If anyone has any experience/suggestions on this please comment
48 Patient Management Addressing Culture Obstacles Involve both the treatment staff and the patient population Two long-established expectations that HINDER recovery: 1) that only a 12-Step approach is acceptable OR 2) that every patient deserves opioid substitution meds Requires team education on the research that counseling alone is worse than counseling + an FDA-approved med Also, team needs to hear health economics findings: Counseling-only care is wasteful, vs. counseling + MAT. Teams need to talk with Vivitrol-treated patients who also used counseling and mutual-help Supervisors: Need to review weekly LIST of supervisees patients & last/missed visit Teams: Need to review weekly LIST of team s patients & last/missed visit info
49 Patient Management Overcoming Logistic Hurdles The preferred situation: Fully establish logistics before patient care This is not always the case Important to mentor RE key front desk personnel responsibilities, insurance coverage determination/managed care interaction, specialty pharmacy ordering, shipping readiness confirmation, cold storage/shelf-life & product tracking, supply management. Mobilize the treatment system to overcome specific logistical hurdles Set up PRE-VISIT ORDERING/SHIPPING procedures from 1 st prescription Set up patient phone call reminders 2 days before injection & follow-up Set up Spouse/Significant Other authorizations for contact if no-shows
50 Problem Solving Converting Screenings into Medication Administrations In medicine, patients accept most treatment recommendations made by their physician In addiction, well under 50% of patients screened eligible for Vivitrol actually get injected The largest cause of drop-off is lack of readiness for definitive care, due to the motivational disruption of addictive disease This problem is followed by culture obstacles in the treatment environment Patient failure to engage is commonly due to: detoxification procedures that create delays incomplete/ineffective withdrawal
51 Patient Management Up Front: Achieving Patient Readiness Key patient messages The nature of the disease: out-of-control, chronic, relapsing, life-threatening XR-NTX: highly effective for preventing relapse to opioid dependence XR-NTX: craving & drug use early in recovery enhances self-efficacy XR-NTX: trigger responses without emotional or cognitive side effects Side effects can occur & can usually be addressed so let us know Program will help with: Scheduling, reminder calls, supportive other F/U calls, justice system communications/tracking Vivitrol Ambassadors have been very successful; a recovery support Vivitrol Groups to increase efficiency, foster retention & persistence
52 Patient Management Patient Retention Patients must see the need for longitudinal care & mutual-help; anticipate relapse risks & loss of motivation. Coordinate messaging & visit reminders with patients, supportive others, program & justice system staff Educate Supportive Others/Family Obtain consent to involve 1 supportive others for initial & follow-up to reinforce safety & retention with both MAT & counseling Address Drug-Seeking, Persistence Issues & Diversion Heighten vigilance for the blockade testing, overriding or seeking opioids to divert for income despite Vivitrol Address blockade avoidance (late re-injection, premature discontinuation) Monitor patients attendance & urine drug tests Timely communication across addiction, medical & justice teams, significant others/family Re-assess/modify treatment plan when escalation is needed, not just the meds
53 Patient Management Co-occurring Disorders Management Medication Discontinuation Planning & Follow-Up XR-NTX is long-term treatment XR-NTX lacks WD; only needed to stabilize craving, establish disease acceptance & recovery The Team + patient must determine Vivitrol s duration: use ASAM Based on treatment engagement, recovery effort & function Post Medication Outcome Tracking Addiction is chronic; must track patients after MAT & determine need to restart before new physiological dependence (avoids detox), before other morbidity & while opportunity to re-engage is open Get follow-up reports on post-mat outcomes & advise RE patient s need for re-assessment & med re-start
54 Patient Management Drug-Drug Interactions There are few drug interactions with XR-NTX (except for opioids) Precipitated opioid withdrawal not a side effect, but is an adverse event Encourage calls to report; monitor induction closely for success Adverse Events Early learning curve for BOTH counselors & patients Common mild-moderate side effects: Nausea (1 st 3 days of 1 st shot) Site tenderness These are expected: Anticipate routinely with every patient & address readily Serious Adverse Events May require emergency room or surgical evaluation or treatment (rare).
55 XR-NTX Continuation Post-Pain AE Percent of Subjects Percent of AEs 8% 5% AEs potentially associated with study discontinuation AEs not associated with study discontinuation N=302 N=481 92% 95% ~92% of subjects reporting receipt of a pain med for a pain-related AE received at least one more XR-NTX dose ~95% of all pain-related AEs reported were not associated with study discontinuation* *As defined by no additional XR-NTX doses after the dosing of pain medication for a pain-related AE (Note: AEs or SAEs occurring >7 weeks after previous XR-NTX dosing were omitted from our analysis).
56 4 th Week Effect? Discontinuation
57 XR-NTX: 4 th Week Effect Anecdotally, patients report XR-NTX wearing off by 4 th week Russian Phase IV RCT analyzed week-by-week findings Week 4 did show: craving, drug use, dropout BUT, at the same rate in BOTH XR-NTX and Placebo groups Conclusion: 4 th Week Effect is real, BUT non-pharmacological Therefore, counseling must address expectancy/ambivalence Anticipate the 4 th week effect from the start of treatment With the patient, caregivers & supportive others Prepare for re-injection with counseling & contingency management
58 HOW LONG? ASAM Criteria Treatment Plan Use CRITERIA for XR-NTX Discontinuation: Patient has Dimension 1: Consistent period of no alcohol or drug use Dimension 2: Stable health management; no SUD complications Dimension 3: Stable MH management; no SUD complications Dimension 4: Readiness Good disease awareness/acceptance Dimension 5: Self-knowledge of risks, triggers & vulnerabilities Success enduring both negative AND positive stressors Dimension 6: Active recovery efforts & lifestyle Stable participation, vocationally & socially
59 Counseling VIVITROL Patients for Recovery Clinical Phenomena Commonly Seen with XR-NTX (Implications: Both good & bad) My friend had this Suboxone that really helped me That guy who got the shot: I wanna be on whatever he s on The Pink Cloud this SH*! works HELP, I m STUCK without an escape for 30 days!!! OK, I m good to go now [silence Elvis has left the building]
60 Counseling VIVITROL Patients for Recovery Why? Because addiction is TOUGH & recovery is painful What? Integrated XR-NTX + counseling yields BEST results Who? Patients who are prepped for long-term treatment How? With realistic expectations, supports, monitoring & program internal accountability structures, discontinuing by planned criteria
Medical Assisted Treatment of Opioid Dependence with XR-NTX(Vivitrol) Michael McNamara DO, FACN Medical Director Mental Health Center of Greater Manchester Manchester NH Outline Overview of Opioid Dependence
Treatment Alternatives for Substance Use Disorders Dean Drosnes, MD, FASAM Associate Medical Director Director, Chronic Pain and SUD Program Caron Treatment Centers 1 Disclosure The speaker has no conflict
Injectable naltrexone (XR-NTX) A RETROSPECTIVE STUDY OF ITS ACCEPTANCE IN A COMMUNITY RECOVERY SETTING BRIANNE FITZGERALD MSN, PMHNP, CARN-AP Overview Gavin Foundation Injectable naltrexone Community report
Serious Mental Illness and Opioid Use Disorder Serious Mental Illness and Opioid Use Disorders Arthur Robin Williams, MD MBE Columbia University, Department of Psychiatry Nick Szubiak, MSW, LCSW Director,
Your Child s Treatment Roadmap The road to recovery isn t the same for everyone. There are many options to consider for your son, daughter, or loved one. Our guide outlines key steps to help you make the
Treatment Approaches for Drug Addiction NOTE: This fact sheet discusses research findings on effective treatment approaches for drug abuse and addiction. If you re seeking treatment, you can call the Substance
Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5
SUBOXONE AND VIVITROL: ARE THERE DISPARITIES SURFACING IN MEDICATION ASSISTED TREATMENTS? P R E S E N T E D B Y D R. K I AM E M AH A N I A H & D R. M Y E C H I A M I N T E R - J O R D AN GOALS AND OBJECTIVES
FY17 SCOPE OF WORK TEMPLATE Name of Program/Services: Medication-Assisted Treatment: Buprenorphine Procedure Code: Modification of 99212, 99213 and 99214: 99212 22 99213 22 99214 22 Definitions: Buprenorphine
Many Types of Approaches Biological Addictions Treatment Psychology 470 Introduction to Chemical Additions Steven E. Meier, Ph.D. Listen to the audio lecture while viewing these slides Detoxification approaches
Understanding Addiction: Why Can t Those Affected Just Say No? 1 The Stigma of Addiction There continues to be a stigma surrounding addiction even among health care workers. Consider the negative opinions
OUTPATIENT TREATMENT WESTPORT, CONNECTICUT ABOUT CLEARPOINT At Clearpoint, we focus on healing the whole person: mind, body, and spirit. Our comprehensive care methods set clients up for long-term success
Opioids Research to Practice CRIT/FIT 2016 April 2016 Daniel P. Alford, MD, MPH Associate Professor of Medicine Assistant Dean, Continuing Medical Education Director, Clinical Addiction Research and Education
The Chronic Disease of Addiction Evidence and Lessons from Practice Laura G. Kehoe, MD, MPH Medical Director, MGH Substance Use Disorders Unit Bridge Clinic Massachusetts General Hospital Assistant Professor
Recovery U: Medication Assisted Treatment (MAT) MS. TIKKANEN: Welcome to the Recovery U Online Learning Community for Understanding Medication-Assisted Treatment. This is Skye Tikkanen. I am a clinical
The Role of Primary Care Teams and the Medical Neighborhood in Addressing the Opioid Crisis in Maine March 10, 2016 Objectives Review current state of opioid crisis in Maine Briefly review physiology of
V. EVIDENCE-BASED APPROACHES TO TREATING ADOLESCENT SUBSTANCE USE DISORDERS R esearch evidence supports the effectiveness of various substance abuse treatment approaches for adolescents. Examples of specific
THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept. Public Health disclosures Dr. Martin has no conflict of interest to disclose.
Women and opioid use disorder: Optimizing care during pregnancy and beyond Susanne Astrab Fogger, DNP, PMHNP-BC, CARN-AP, FAANP Ashley L. Hodges, PhD, CRNP, WHNP-BC Disclosures Dr. Fogger has nothing to
P ford residence southampton, ny Naltrexone protocol alcohol The premier alcohol treatment program. Control or eliminate alcohol use using the Sinclair Method A Non 12-Step Outpatient Program. If you would
CONTRAVE IS THE #1 PRESCRIBED WEIGHT-LOSS BRAND* DID YOU KNOW... 9 out of 10 people struggle with food cravings while dieting? Help control your cravings and lose weight with CONTRAVE The exact neurochemical
The role of behavioral interventions in buprenorphine treatment of opioid use disorders Roger D. Weiss, MD Harvard Medical School, Boston, MA, McLean Hospital, Belmont, MA, USA Today s talk Review of studies
Substance and Alcohol Related Disorders Substance use Disorder Alcoholism Gambling Disorder What is a Substance Use Disorder? According to the DSM-5, a substance use disorder describes a problematic pattern
Prepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry In broad terms, substance use disorders occur when a substance is used in a compulsive manner with a lack of control over
ASSISTING PATIENTS with QUITTING CLINICAL PRACTICE GUIDELINE for TREATING TOBACCO USE and DEPENDENCE Released June 2000 Sponsored by the AHRQ (Agency for Healthcare Research and Quality) of the USPHS (US
Substance Use Disorders in Primary Care Jin Hee Yoon-Hudman, MD Assistant Vice President, Medical Director, Behavioral Health Healthfirst Fall Symposium Prevention as a Priority in Value-Based Healthcare,
+ Contingency Management with Adolescents and Their Families Evidencebased approach for treating adolescent substance abuse Promotes positive behaviors and addresses ambivalence Strength- Based, Family-
INFORMATION FOR FEDERAL PRISONERS IN BRITISH COLUMBIA Methadone Treatment in federal prison This booklet will explain how to qualify for Methadone treatment in prison, the requirements of the Correctional
Beginning the Journey Alcohol & Drug Addiction Recovery Helping a Loved One with an Addiction ADRC of Brown County 920-448-4300 300 S. Adams Street Green Bay, WI 54301 adrcofbrowncounty.org facebook.com/adrcbrowncountywi
Responding to the Opioid Epidemic Jessica Gray, MD Addiction Medicine Fellow Boston Medical Center ROME New England August 17, 2017 Disclosures for Jessica Gray, MD No conflicts Learning Objectives Describe
Appendix F Federation of State Medical Boards Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office SECTION I: PREAMBLE The (name of board) recognizes that the prevalence of addiction
HOUSE Calls Published by the Alachua County Medical Society Winter 2017 Addiction Medicine Addiction as a Disease Gregory L. Jones, MD, FASAM, FAAF, UF Health Florida Recovery Center Scott A. Teitelbaum,
Marriage Parenting Spiritual Growth Sexuality Relationships Mental Health Men Women Hurts and Emotions Singles Ministers and Mentors Technology a resource in: Mental Health What To Expect From Counseling
EVEN IF YOU KNOW ABOUT DRINKING OR DRUGS Simple Questions. Straight Answers. WHY IS MY HEALTHCARE PROVIDER ASKING ME ABOUT ALCOHOL AND OTHER DRUGS? Asking these questions is part of good health care, just
Extended Release Naltrexone Vivitrol Christopher J Davis D.O. CAADC, FASAM Medical Director, Brightwater Landing Medical Director, Pyramid Healthcare Diplomate of The American Board of Addition Medicine
2017 State Targeted Response to the Opioid Crisis Grants QUARTERLY PROVIDER MEETING MARCH 9, 2017 SUZANNE BORYS, ED.D. H.R.6-21st Century Cures Act The 21st Century Cures Act is a United States law enacted
SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets Risk Evaluation and Mitigation Strategy (REMS) Program Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Prescribers
Division of Mental Health and Addiction Services A DAM BUCON, LSW DMHAS Mission DMHAS, in partnership with consumers, family members, providers and other stakeholders, promotes wellness and recovery for
Addictions Pharmacotherapy Thomas Kosten MD Associate Vice President for Research JH Waggoner Chair & Professor of Psychiatry, Pharmacology & Neuroscience Baylor College of Medicine Disclosure Thomas Kosten,
+ Buprenorphine for Family Medicine Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17 + Disclosures No conflicts of interest Off-label use of medications + Who here: Has taken care of a patient
Integrated Care for Depression, Anxiety and PTSD University of Washington An Evidence-based d Approach for Behavioral Health Professionals (LCSWs, MFTs, and RNs) Alameda Health Consortium November 15-16,
Chapter II Practitioner Guidelines for Enhanced IMR for COD Handout #2: Practical Facts About Mental Illness There are four handouts to choose from, depending on the client and his or her diagnosis: 2A:
Mental Health Strategy Easy Read Mental Health Strategy Easy Read The Scottish Government, Edinburgh 2012 Crown copyright 2012 You may re-use this information (excluding logos and images) free of charge
Practical Approach to Office Based Addiction Treatment ELIZABETH A DAVIS, MD SOUTH END COMMUNITY HEALTH CENTER BOSTON, MA AUGUST 17, 2017 Objectives To understand Impact of addiction as a public health
BERNALILLO COUNTY OPIOID ABUSE ACCOUNTABILITY SUMMIT Turning the Curve on Opioid Abuse in Bernalillo County NMPHA Annual Conference April 2, 2014 Marsha McMurray-Avila Coordinator, Bernalillo County Community
Overview of Opioid Use Disorder Doug Burgess, MD Medical Director of Outpatient Services, Truman Medical Centers Assistant Professor of Psychiatry, University of Missouri- Kansas City Objectives History
Helping Someone Quit Smoking Smart Steps to help make it easier 1-866-710-QUIT (7848) albertaquits.ca Ready to help someone quit? Kudos on wanting to help someone in your life quit smoking. Friends, family,
Mood Disorders for Care Coordinators David A Harrison, MD, PhD Assistant Professor, Dept of Psychiatry & Behavioral Sciences University of Washington School of Medicine Introduction 1 of 3 Mood disorders
Notes from filming at White River VA-February 5, 2008 Wellness Tools Go fishing Shut down and think, what to do and what not to do Get into a good book Drawing Focus on something other than negatives Be
Taking Opioids Responsibly for Your Safety and the Safety of Others: Patient Information Guide on Long-term Opioid Therapy for Chronic Pain Department of Veterans Affairs (VA) and Department of Defense
How serious is the opiate problem in Fairfield County? The Use of Opiates in Fairfield County has increased from levels in the 1990's that were barely detectable to epidemic proportions in 2010. How serious
SUBSTANCE USE DISORDER TREATMENT AND REFERRAL PROCESS Presented by: John M. Connolly, Ph.D. Acting Deputy Director Los Angeles County Health Agency Department of Public Health Substance Abuse Prevention
Aligning Evidence-Based Practices with CCBHC Financing, Operations, and Quality Reporting October 25th, 2017 2:00pm 3:00pm Webinar Login Directions Recommend calling in on your telephone. Enter your unique
Tobacco cessation overview calendar 21-Day Countdown to Quitting Session 1: Days 1-3 List health benefits of quitting. List expectations of overcoming your habits and addictions. List your top three Schedule
The Clinical Level of Care Guidelines contained on the following pages have been developed as a guide to assist care managers, physicians and providers in making medical necessity decisions about the least
TREATMENT I m the type of person that once I start using, there is no, well, I m going to go to detox. I have to be locked up. And if I m not locked up, I will continue until some very big disaster happens.
Hull & East Riding Prescribing Committee Prescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence) Patients Name: Unit Number: Patients Address:.. G.P s Name:.. Communication We agree
OPIATES IN PRISON Jeffrey C. Fetter, MD Agenda Opioids in the Correctional Environment MAT and Corrections Substance Abuse Treatment in NH DOC Suboxone Suboxone: Contraband Suboxone Contraband Scale of
Minneapolis VA s Intensive Outpatient Program (IOP): Screening, Treating, and Tracking Veterans Stephanie Bertucci, LICSW, IOP Coordinator Marcus Moore, Certified Peer Specialist Daniel Silversmith, PsyD,
1 Treatment Planning Tools ASI-MV These Treatment Planning Tools summarize the client s self-reported data from the ASI-MV. When used in conjunction with the Problem Lists & Key Clusters and the ASI-MV
FREEDOM SUBSTANCE ABUSE TREATMENT APPLICATION/REQUIREMENTS for ADMISSION PURPOSE: Our primary goal is to facilitate a stable environment that gives individuals an opportunity to break the cycle of homelessness
Effective Treatment: Doing the Right Thing, In the Right Way Terrence D Walton, MSW, ICADC Monitor Manage Impact 1. Understand the Treatment Field, including Evidenced Based Practices 2. Understand Your
DOLLARS AND SENSE: THE COST OF SUBSTANCE ABUSE TO MISSOURI SCOPE OF THE PROBLEM Alcohol and other drug abuse is ranked the most costly health care issue in the United States. Substance abuse and addiction
Medical Necessity Criteria 2017 The New Directions Medical Necessity Criteria have been revised. The new version will be effective January 1, 2017. See https://www.ndbh.com/providers/behavioralhealthplanproviders.aspx.
The Smoking Gun: for Smoking Cessation in Patients with Mental Health Disorders BRENDON HOGAN, PHARMD PGY2 PSYCHIATRIC PHARMACY RESIDENT CTVHCS, TEMPLE, TX 09/23/2016 I would feel comfortable dispensing/prescribing
Integrating Tobacco Cessation into Practice Presented To Smoking Cessation Leadership Center PIONEERS FOR SMOKING CESSATION CAMPAIGN By Carol Southard, RN, MSN Tobacco Treatment Specialist Northwestern
Problem Situation Form for Parents Please complete a form for each situation you notice causes your child social anxiety. 1. WHAT WAS THE SITUATION? Please describe what happened. Provide enough information
Community-based sanctions... community-based sanctions used as alternatives to incarceration are a good investment in public safety. Compared with incarceration, they do not result in higher rates of criminal
Post-Traumatic Stress Disorder Teena Jain 2017 Post-Traumatic Stress Disorder What is post-traumatic stress disorder, or PTSD? PTSD is a disorder that some people develop after experiencing a shocking,
Guide to Helping Your Loved One Accept and Discover ADDICTION RECOVERY 2 More than 22 million people over age 12 were classified with substance dependence or abuse between 2012 and 2013, according to the
LANCASTER COUNTY DRUG AND ALCOHOL COMMISSION Helping Others Get Help For Alcohol and Other Drug Problems 150 North Queen Street (717) 299-8023 Fax: (717) 293-7252 Rick Kastner Executive Director Rev: January
CSAM-SCAM Fundamentals Intro to Concurrent Disorders Presentation provided by Jennifer Brasch, MD, FRCPC Psychiatrist, Concurrent Disorders Program, St. Joseph s Healthcare There are all kinds of addicts,
Department of Public Health Bureau of Substance Abuse Services - BSAS Luisa Fundora, MSW Regional Manager BSAS/ MA DPH Bureau of Substance Abuse Services The Bureau of Substance Abuse Services (BSAS) is
FACING ADDICTION OVER DINNER The NATIONAL NIGHT of CONVERSATION November 17, 2016 The dinner table is one of the most important places in the house for improving the health of your family, but not only
Statement of Inclusivity and Ethics Hemma Community Acupuncture strives to create a safe and comfortable environment for all members of our community. We welcome people of all genders, sexes, races, colours,
2016 MATCP Conference Research Says Best Practices in Assessment, Management, and Treatment of Impaired Drivers Mark Stodola Probation Fellow American Probation and Parole Association Provide participants
Resist the Opioid Pendulum: Understanding Opioids and Pain, and how they relate to Addiction Stefan G. Kertesz, MD, MSc Diplomate, American Board of Addiction Medicine Associate Professor, University of